Lumen Bioscience Details 2022 Company and Facilities Growth, New Funding, and Clinical Pipeline Progress
Summary
Progress across all commercial and charitable clinical research programs $36 million in new funding in 2H2022, including major new research grants and equitySEATTLE, Jan. 5, 2023 /PRNewswire/ -- Lumen Bioscience a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases today provided a review of the companys 2022 growth, including progress in its clinical development programs, GMP manufacturing expansion, and funding. 2022 progress includes: FDA cleared IND application supporting a Phase 2/3 multi-center, placebo-controlled trial to evaluate the efficacy of LMN-201 in preventing C. difficile recurrence (NCT05330182). Lumen also made strong progress in the CARB-X-funded program to develop a broad antibody cocktail offering protection against most clinically important strains of ETEC and C. jejuni. Lumen announced multiple non-dilutive funding in the second half of 2022, including significant new support from BARDA, CARBX, The Bill & Melinda Gates Foundation, and USAMRD/MTEC ($20 million total).Lumen Bioscience discovers, develops, and manufactures biologic drug candidates for highly prevalent diseasesmany of which currently lack effective treatments. The companys unique drug development and manufacturing platform offers the potential to transform the biologics industry through increased speed, mass-market scale, and exponentially lower costs than current approaches.